Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF SEC filings (Ticker: IMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IMRA SEC filings page on Stock Titan provides a view into the regulatory record associated with the IMRA ticker and its corporate history. IMRA is identified as Bitwise MARA Option Income Strategy ETF, and the symbol has also been historically linked to Imara Inc., which later merged with Enliven Therapeutics, Inc. For investors and researchers, understanding this evolution is important when reviewing filings and related documents.
Historical Imara filings, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K referenced in company news releases, contain detailed disclosures about Imara’s clinical-stage biotechnology activities. These documents describe programs including tovinontrine (IMR-687), a PDE9 inhibitor in Phase 2b clinical trials for sickle cell disease and beta-thalassemia and in development for heart failure with preserved ejection fraction, and IMR-261, an oral Nrf2 activator with preclinical data in hemoglobin and iron overload-related disorders. They also discuss clinical trial design, risk factors, and other regulatory information.
Merger-related filings, including a registration statement on Form S-4 referenced in the merger announcements, outline the terms of the all-stock transaction between Imara and Enliven Therapeutics, Inc., the planned issuance of shares, and the subsequent renaming of the combined company to Enliven Therapeutics, Inc. Later, an 8-K filing excerpt shows Enliven Therapeutics, Inc. as the registrant with common stock listed on the Nasdaq Global Select Market under the symbol ELVN, and includes information about matters submitted to a vote of stockholders.
On Stock Titan, users can access these types of filings and benefit from AI-powered summaries that explain key points in plain language, highlight material events, and help interpret complex sections in documents such as 10-Ks, 10-Qs, 8-Ks, proxy statements, and other forms. For symbols with a history like IMRA, this can clarify how earlier Imara disclosures connect to the current Enliven Therapeutics, Inc. listing under ELVN and to the separate identification of IMRA as Bitwise MARA Option Income Strategy ETF.
Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock under a pre-established Rule 10b5-1 plan. The filing shows 6,667 shares sold on 09/08/2025 at a weighted average price of $20.2426, leaving beneficial ownership of 283,308 shares held indirectly by The Patel / Dong Family Trust. The 10b5-1 trading plan was adopted on September 30, 2024, and the sale was executed in multiple trades at prices ranging from $19.915 to $20.64. The Form 4 was signed by a power of attorney on 09/10/2025. The filer offers to provide, upon request, the breakdown of shares sold at each execution price.
Form 144 notice for proposed sale of Enliven Therapeutics common stock. The filer plans to sell 20,001 shares through Jefferies LLC with an aggregate market value of $403,020.15, to be executed on or about 09/08/2025 on Nasdaq. The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filer reported two prior sales in the past three months totaling 13,334 shares with gross proceeds of $253,566.41. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), reported option exercise and subsequent sale of shares under a Rule 10b5-1 plan. On 08/27/2025 the reporting person exercised a stock option with a $2.48 exercise price to acquire 3,250 shares that were fully vested and exercisable, and then sold 3,250 shares in multiple trades at a weighted-average sale price of $20.6273, reducing his beneficial ownership to 23,000 shares. The filings state the transactions were effected pursuant to a 10b5-1 trading plan adopted on June 26, 2023, and the sale prices ranged from $20.27 to $20.8689.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 5,250 common shares through Jefferies LLC on 08/27/2025, with an aggregate market value of $106,680.00. The securities were acquired on 08/09/2022 via stock options from Enliven Therapeutics. The filer reports 59,000,000 shares outstanding. The filing also discloses four prior sales by Benjamin Hohl totaling 10,500 shares on dates in June and July 2025 with the recorded gross proceeds for each sale.
Samuel Kintz, President & CEO and Director of Enliven Therapeutics, Inc. (ELVN), reported an amended Form 4 showing a small open-market sale. The amendment corrects the original filing to reflect the disposition of 1,517 shares sold on 08/20/2025 under a Rule 10b5-1 trading plan adopted 11/15/2024 at a weighted average price of $20.0023 per share. After the sale, the reporting person beneficially owns 927,892 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee.
The amended filing was signed by power of attorney on 08/21/2025. The filer notes the sale was effected in multiple trades and offers to provide detailed execution prices on request.
Enliven Therapeutics insider sale under 10b5-1 plan. Chief Scientific Officer Joseph P. Lyssikatos reported two sales of Enliven Therapeutics (ELVN) common stock: 5,000 shares sold on 08/19/2025 at a weighted average price of $19.6235 and 7,500 shares sold on 08/21/2025 at a weighted average price of $20.0132. The Form 4 states these sales were effected pursuant to a Rule 10b5-1 trading plan adopted November 15, 2024. Following the 08/19 sale the reporting person beneficially owned 947,688 shares; following the 08/21 sale the beneficial ownership was 940,188 shares. The shares are held indirectly through The Lyssikatos Revocable Trust dated 12/15/2011, for which Mr. Lyssikatos serves as trustee. The Form 4 is signed by an attorney-in-fact, Ben Hohl.
Insider sales by Enliven Therapeutics director and CEO Samuel Kintz were reported on Form 4. The filing shows Mr. Kintz, as trustee of The Kintz & Egan Trust Dated March 30, 2019, sold 10,393 shares of Enliven common stock on 08/18/2025 at a weighted average price of $20.0237 and sold 590 shares on 08/19/2025 at $20. After these transactions the trust beneficially owned 929,409 shares. The sales were executed under a Rule 10b5-1 trading plan adopted November 15, 2024. The Form 4 was signed by Ben Hohl by power of attorney on 08/20/2025.
The filing notifies a proposed sale of 12,500 common shares of the issuer to be executed through Jefferies LLC on 08/19/2025 with an aggregate market value of $246,875.00. The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filer reported recent sales during the past three months: 7,500 shares on 06/03/2025 for $150,219.98, 12,500 shares on 06/20/2025 for $267,457.63, and 12,500 shares on 07/21/2025 for $278,646.38. The filing includes a representation that the seller is not aware of material nonpublic information.
Form 144 notice for proposed resale by an affiliate. The filing reports a planned sale of 12,500 common shares through Jefferies LLC (520 Madison Ave, New York) with an aggregate market value of $252,750 and an approximate sale date of 08/18/2025 on Nasdaq. The filing lists total shares outstanding as 59,000,000.
The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics and the filer indicates payment was not applicable. The filer has disclosed recent cash sales of the same issuer during the past three months: 7,500 shares on 06/03/2025 for $150,351.60; 12,500 shares on 06/17/2025 for $277,292.48; and 12,500 shares on 07/17/2025 for $281,517.75. The notice includes the required attestation that the seller is not aware of undisclosed material adverse information.
Commodore Capital and affiliated filers disclosed beneficial ownership of 6,022,957 shares of Enliven Therapeutics, Inc., representing 9.9% of the outstanding common stock as of June 30, 2025. The total includes 4,692,809 currently held shares and 1,330,148 shares issuable upon exercise of a pre-funded warrant subject to a 9.99% beneficial ownership limitation. The filing shows shared voting and dispositive power over all 6,022,957 shares and states the Firm acts as investment manager to Commodore Capital Master LP; managing partners Michael Kramarz and Robert Egen Atkinson exercise investment discretion. Signatures are dated August 14, 2025.
FAQ
What is the current stock price of Bitwise MARA Option Income Strategy ETF (IMRA)?
